While normal hematopoietic progenitor cells are dependent on colony-stimulating factors for in vitro proliferation, myeloid leukemic cells are frequently factor-independent. In this study we investigated several signalling intermediates of the Ras-Erk1,2 pathway which may be involved in the development of growth factor independence. In the growth factor independent cell line KG1, an extremely short activation pattern of Erk1,2 with a maximum at 30 s was observed in response to FBS. In contrast, stimulation of the IL-3 receptor in AML193 cells resulted in a transient Erk activation peaking at 5 min and returning to base levels after 15 min. Although the Erk activation in KG1 cells is short-lived, using the MEK inhibitor PD98059, we demonstrated that Erk phosphorylation is essential for proliferation of these cell lines. We also detected major differences in Shc phosphorylation between factor-dependent and -independent cells. These data suggest that Erk activation is essential for proliferation of growth factor-dependent and -independent leukemic cells. The minimal Erk activation observed in KG1 cells in response to serum is sufficient for mitogenesis of these cells.
Introduction
Proliferation of normal hematopoietic cells is strictly growth factor dependent, whereas leukemic cell lines and primary leukemic cells often show partial or complete growth factor independence. Various mechanisms may result in factor-independence. Occasionally leukemic cells have acquired the capacity to secrete autocrine growth factors in vitro, which may explain the process of factor-independence. 1, 2 It is also conceivable that mutations in the signal transduction pathways or in growth controlling genes of leukemic cells are responsible for growth factor independence. To understand the conversion of leukemic cells towards factor independence better, we explored several components of the proliferative signalling pathways of the growth factor-independent, human myeloid leukemic cell line KG1 and the IL-3-dependent cell line AML193.
KG1 cells proliferate in response to serum (FBS), but not to hematopoietic growth factors although high affinity receptors for IL-3 and GM-CSF are present on these cells. [3] [4] [5] [6] In contrast, AML193 cells exhibit a dose-dependent proliferative response to IL-3. IL-3 belongs to the family of hematopoietic growth factors. The corresponding receptors for these factors lack endogenous tyrosine kinase activity but mediate their responses by using JAK proteins for tyrosine phosphorylation of the activated receptor. [7] [8] [9] The phosphorylated receptors then stimulate intracellular signalling cascades by binding and activating cytoplasmic proteins. Many of these proteins share Correspondence: JA Maassen, Department of Molecular Cell Biology, Sylvius Laboratory, Wassenaarseweg 72, 2333 AL Leiden, The Netherlands; Fax: 31 71 527 6284 RMYB and JD contributed equally to this work Received 2 June 1997; accepted 6 January 1998 a common structural motif, the Src homology 2 (SH2) domain, that plays a role as docking site for other tyrosine phosphorylated proteins. Two SH2 domain containing proteins, SHC and Grb2, link activated receptors to the Ras pathway.
10,11 Shc becomes transiently tyrosine phosphorylated in myeloid cells after stimulation with GM-CSF, IL-3 and c-kit and binds to Grb2. 12, 13 Grb2 shuttles the Ras guanine nucleotide exchange factor Sos1 to Ras so that Sos1 can activate Ras by catalysing the exchange of GDP for GTP.
14 Ras.GTP subsequently activates via a cascade of serine/threonine kinases the extracellular signal regulated kinases (Erks) which finally deliver mitogenic signals received at the plasma membrane to targets in the nucleus. 15, 16 Other protein kinases such as protein kinase C (PKC) and protein kinase A (PKA) have been found to interact with the proliferative signalling pathways.
In this study, we investigated the activation pattern of Erk1,2 and its relation to the proliferative response of growth factorindependent leukemic cells (KG1) and IL-3-dependent cells (AML193). Furthermore, we studied upstream signalling intermediates leading to Ras activation in these cell lines.
Materials and methods

Materials
32
P-orthophosphate (acid free; carrier free), methyl-3 H-thymidine, and ECL protein detection system were purchased from Amersham Life Science (Amersham, UK); phosphate-free RPMI 1640, O-tetradecanoyl phorbol-13-acetate (TPA) and sodium-ortho-vanadate were from Sigma Chemicals (Bornem, Belgium); human serum albumin (HSA) was from The Central Laboratory of the Netherlands Red Cross Blood Transfusion Service (Amsterdam, The Netherlands); IL-3 was kindly provided by Sandoz (Basel, Switzerland); RPMI 1640 culture medium and fetal bovine serum (FBS) were from Gibco Life Technologies (Breda, The Netherlands); Protein-G and -A Sepharose beads were purchased from Pharmacia Biotech Benelux (Roosendaal, The Netherlands); PD98059 was purchased from Parke-Davis (Ann Arbor, MI, USA).
Antibodies
Polyclonal Erk1 antiserum 691, recognising the 42-and 44 kDa isoforms of Erk, and monoclonal protein kinase C (PKC) antiserum (MC5), recognizing ␣, ␤ and ␥ isoforms of PKC, were purchased from Santa-Cruz Biotechnology Inc (SantaCruz, CA, USA); the monoclonal anti-phosphotyrosine antibody 4G10 was from Upstate Biotechnology Inc (Lake Placid, NY, USA); horseradish peroxidase (HRP)-conjugated second antibodies were from Promega (Leiden, The Netherlands); affinity-purified polyclonal anti-Shc antibody was kindly 700 provided by Prof Dr JL Bos, University of Utrecht, The Netherlands.
Cell lines and culture
The human myeloid leukemic cell lines KG1 and AML193 were obtained from ATCC (Rockville, MD, USA). The KG1 and AML193 cell lines were cultured in RPMI 1640 culture medium supplemented with glutamine, penicillin/ streptomycin, amphotericin and 10% FBS (KG1 cells) or 10% human serum (AML193 cells). Culture medium of the AML193 was supplemented with 10 ng/ml IL-3. Prior to each experiment the cells were serum-and growth factor-deprived for 24 h (AML193) or 48 h (KG1) in culture medium containing 0.1% human albumin.
Detection of the activation status of Shc
In AML193 cells, phosphorylation of Shc was examined using immunoblots of anti-Shc immunoprecipitates with antiphosphotyrosine antibody. Growth arrested AML193 cells were treated with IL-3, washed twice with PBS and lysed in buffer containing 20 mM Tris (pH 8.0), 137 mM NaCl, 10 mM EDTA, 1% NP40, 100 mM NaF, 1 mM DTT, 10% glycerol, 2 mM Na 3 VO 4 and protease inhibitors. Nuclei were removed by centrifugation at 10 000 g for 10 min and the supernatant was incubated with polyclonal anti-Shc antibody for 4 h, followed by protein A-Sepharose for 1 h. Immunoprecipitates were washed four times and resuspended in SDS sample buffer containing 10% glycerol, 5% mercaptoethanol, 3% SDS, 100 mM Tris.PO 4 (pH 6.8) and 0.01% bromophenol blue. Proteins were separated on 7.5% SDS PAGE and transferred to Immobilon filters (Millipore, Bedford, MA, USA). Filters were incubated with 4G10 followed by incubation with goat-anti-rabbit IgG conjugated to HRP. Bound conjugates were visualized by ECL.
The phosphorylation status of Shc in KG1 cells was examined by immunoprecipitation of Shc from 32 P-phosphatelabelled cells. Serum-starved KG1 cells were labelled with 32 P-orthophosphate (0.4 mCi/ml) in phosphate-free RPMI supplemented with 0.1% HSA for 18 h. The cells were stimulated with 10% FBS, washed twice with cold PBS and lysed in 1% NP40, 10% glycerol, 30 mM Tris (pH 7.5), 2 mM EDTA, 150 mM NaCl, 1 mM Na 3 VO 4 , 10 mM NaF and protease inhibitors. Nuclei were removed by centrifugation at 10 000 g for 10 min and the supernatant was incubated with polyclonal anti-Shc antibody coupled to Protein G-Sepharose beads for 4 h at 4°C. Immunoprecipitations were washed four times and collected in SDS sample buffer. Proteins were separated by 10% SDS-PAGE and visualized by autoradiography.
Erk and PKC immunoblotting
After stimulation, cells were washed twice with ice-cold PBS and lysed in SDS-sample buffer. Proteins (30 g protein per lane) were separated by SDS-PAGE and transferred to Immobilon filters. Erk1,2 phosphorylation was reflected by a decreased mobility of the protein as visualized by immunoblotting with Erk antiserum followed by incubation with goat anti-rabbit IgG linked to HRP. ECL detection was performed as described by the manufacturer.
Total PKC levels were determined by immunoblotting with H-thymidine for 6 h and then harvested using the Skatron Filtermat Harvesting system. Filter strips were dried and counted in a liquid scintillation counter. Data were calculated as the mean radioactivity (c.p.m.) of six cultures.
Results
Shc phosphorylation in AML193 and KG1 cells
To determine the activation of signalling intermediates upstream of Erk1,2 in response to growth stimulation, we examined the phosphorylation of Shc in response to IL-3 in AML193 cells and to FBS in KG1 cells, respectively. Figure  1a shows the immunoblot of IL-3-deprived and IL-3-treated AML193 cells. No Shc phosphorylation was detected in growth arrested AML193 cells. IL-3 treatment for 10 min resulted in a strong phosphorylation of a 52 kDa Shc ( Figure  1a ). Reprobing the blot with anti-Shc showed equal loading of proteins in the lanes (data not shown). Similar experiments were performed in KG1 cells. However, these results were not conclusive due to low expression of Shc in these cells which was overshadowed by the strong IgG band. Another method to determine the phosphorylation status of the Shc protein is to perform metabolic labelling with 32 P-phosphate and to analyze immunoprecipitated Shc for 32 P incorporation as described by Ouwens et al. 17 The IgG band is not visualized by this method. Quiescent KG1 cells were labelled with 32 Pphosphate, stimulated with 10% FBS for 15 min and immuno- Time course of Erk1,2 phosphorylation. Growth-arrested AML193 cells were treated for the indicated time periods with 500 ng/ml IL-3 (a). Growth-arrested KG1 cells were treated with 10% FBS for the indicated time periods in the absence (b) or presence of 500 nM sodium orthovanadate (c). Erk1,2 phosphorylation was detected on Western blots with anti-Erk1 antibody. Phosphorylation of Erk1,2 is visualized by a shift of the protein to a lower electrophoretic mobility.
trations IL-3 (Figure 3a) . IL-3 treatment of AML193 cells resulted in a dose-dependent increase in DNA synthesis with a five-fold maximal stimulation (Figure 3b) . PD98059 selectively inhibits MEK activation by binding to the inactive form of MEK without affecting other kinases such as protein kinase A, PKC, Raf or Erk1,2.
18 Therefore, PD98059 offers a highly specific manner of ablating MEK activity and consequent Erk activation. To determine the inhibiting potential of PD98059 on proliferation of growth factor-dependent and -independent leukemic cell lines, we pre-incubated growth arrested KG1 cells and AML193 cells for 30 min with various concentrations of the MEK inhibitor PD98059 followed by the addition of FBS and IL-3, respectively. Both in KG1 and AML193 cells, PD98059 strongly inhibited the increase in DNA synthesis (Figure 3c and d) . No effect of PD98059 was detected on basal 3 H-thymidine incorporation. The IC 50 of PD98059 in KG1 and AML193 cells was 15 and 5 M, respectively, which is similar to values published by others. [18] [19] [20] Figure 4a shows the effect of treatment of the MEK inhibitor PD98059 on FBS-induced Erk1,2 activation in KG1 cells. Pretreatment with 100 M PD98059 for 30 min had a strong inhibitory effect on Erk1,2 activation in KG1 cells. Even the short-lived Erk1,2 activation, as observed in this cell line, was completely suppressed by PD98059. A similar inhibitory effect on Erk1,2 activation by PD98059 was detected in IL-3-stimulated AML193 cells (Figure 4b ). These findings implicate that Erk activation is an essential step in proliferation of both FBS-and IL-3-induced mitogenicity in KG1 and AML193 cells, respectively.
Effect of PKC depletion on serum-induced proliferation in KG1 cells
Protein kinase C is another potent activator of the Erk1,2 pathway, which acts independently of activation of Ras. 21, 22 Since KG1 cells showed no increase in Shc phosphorylation upon FBS treatment and whereas Erk1,2 activation appeared to be important for proliferation of these cells, we explored the possibility that Erk activation might proceed via PKC. To explore this possibility, we cultured quiescent KG1 cells for 24 h with 100 ng/ml TPA to deplete the endogenous PKC levels. Subsequently we determined the effect of FBS on DNA synthesis in PKC depleted and non-depleted KG1 cells. As shown in Figure 5 , PKC depletion does not affect the FBS induced mitogenic response in KG1 cells.
To confirm PKC depletion, we analyzed TPA-induced Erk1,2 activation in PKC-depleted and non-depleted KG1 cells. TPA pre-treatment for 24 h resulted in the entire loss of TPA-induced Erk1,2 activation (Figure 6a ) and in the loss of immunodetectable PKC (Figure 6b ). In addition, no TPAinduced activation of PKC was observed in PKC-depleted KG1 cells (data not shown).
Discussion
In mammalian cells activation of Erk1,2 by growth factors is thought to contribute to cell proliferation and differentiation. Erks are serine/threonine kinases that transduce mitogenic signals generated at the plasma membrane in response to growth factor stimulation to the nucleus to activate specific transcription factors. Activation of the IL-3-receptor in AML193 resulted in a transient Erk1,2 activation, peaking after 5 min Effect of PD98059 on Erk1,2 phosphorylation in KG1 cells (a) and AML193 cells (b). Quiescent KG1 cells were treated with 10% FBS for various time periods in the presence of 100 M PD98059 (a). See Figure 2b for the same experiment without PD98059. Growtharrested AML193 cells were treated with 500 ng/ml IL-3 for 10 min in the absence or presence of 100 M PD98059 (b). These Figures represent one of two independent experiments with similar results.
Figure 5
Effect of PKC depletion on serum induced 3 H-thymidine uptake in KG1 cells. Quiescent cells were cultured in absence or presence of 100 ng/ml TPA. The next day, cells were treated with (filled bars) or without (open bars) FBS and 3 H-thymidine uptake was determined. This experiment was performed in batches of six. Standard deviations are indicated.
Figure 6
Effect of PKC depletion on TPA-induced Erk activation. Growth-arrested KG1 cells were cultured in the absence or presence of 100 ng/ml TPA for 24 h. The next day PKC-depleted and nondepleted cells were left untreated (0) or were stimulated for 5 min with 100 ng/ml TPA. Erk1,2 phosphorylation was detected on Western blots with anti-Erk1 antibody (a). Panel b shows PKC levels by immunoblotting in PKC non-depleted (−) and depleted (+) KG1 cells. and returning to basal levels after 15 min. This time course is similar to the pattern of Erk activation seen in other cell types. However, in the growth factor independent cell line, KG1, an extremely short-lasting activation pattern of Erk1,2, with a maximum at 30 s, was observed in response to FBS. This observation raised the question whether this rapid activation of Erk1,2 is sufficient to translocate Erk to the nucleus and to allow cells to proceed through the cell cycle. PD98059 is a pharmaceutical agent that prevents MEK activation and subsequent Erk activation. This compound does not affect Mekrelated kinases of the stress pathway. Our data showed that prevention of Erk1,2 activation by PD98059 resulted in a complete block of Erk1,2 activation and a strong suppression of the proliferative response of KG1 and AML193 cells. These results demonstrate that Erk1,2 activation is an essential prerequisite for the proliferative response of these cells to hematopoietic growth factors and serum. Erk activation on its own seems insufficient to drive leukemic cells towards proliferation, since treatment of KG1 cells with TPA or vanadate, which both result in a strong sustained Erk activation, does not lead to a mitogenic response in these cells (data not shown). No sustained Erk1,2 activation was detected in KG1 or AML193 cells which were continuously stimulated by FBS or IL-3, respectively. Whether difference in the kinetics of Erk activation in KG1 cells by FBS vs TPA accounts for the observed differences in cellular responses is not known. In experiments with PC12 cells, it has been demonstrated that the duration of Erk1,2 activation is critical for the outcome of different cellular responses (proliferation vs differentiation). 23 Besides the observed differences in Erk activation in hematopoietic growth factor-dependent and -independent leukemic cell lines, we also detected major differences in upstream signalling molecules. High levels of Shc phosphorylation were detected in both serum-starved and serum-treated KG1 cells. These cells also showed constitutively high levels of activated Ras (Ras.GTP) in serum-starved and serum-stimulated KG1 cells (data not shown). These data are in agreement with studies from Okuda et al, 24 who demonstrated that in several growth factor dependent myeloid cells Raf-1 phosphorylation, a downstream event of Ras, was strictly regulated by the addition of growth factors. In contrast, in factor-independent cell lines, including KG1, hyperphosphorylation of Raf-1 was seen in the absence of growth factors. The correlation of hyperphosphorylated Raf-1 with growth factor independence was also observed in primary acute myeloblastic leukemic cells. 24 These findings suggest that the presence of a constitutive activation of the Raf-Ras-Erk pathway is associated with the conversion of growth factor dependent myeloid leukemic cells to growth factor independent cells.
The mechanism by which FBS leads to Shc-independent Erk activation and proliferation in KG1 cells remains unclear. Rasdependent (ie PDGF) and -independent (ie LPA) factors are present in serum. We have tested several growth factors for their mitogenic effect on KG1 cells. No proliferative effect was detected with PDGF, FGF or EGF (data not shown). Previously, we have determined the role of cAMP analogues in Erk1,2 activation and proliferation in KG1 and AML193 cells. 25 In AML193 cells treatment with 8-Br-cAMP leads to Erk1,2 activation as well as to a mitogenic response. However, no effect of 8-Br-cAMP on Erk activation and only a minor proliferative effect was detected in KG1 cells, indicating that activation of PKA is not responsible for the FBS-induced proliferation of KG1 cells. PKC, a well known Ras-independent activator of Erk1,2 in mammalian cells, is also unlikely to be involved in the FBS-induced proliferation of KG1 cells, since PKC depletion did not alter the serum-induced mitogenesis. Moreover, TPA did not induce a mitogenic response in KG1 cells (data not shown).
Despite the presence of high basal Shc phosphorylation and Ras.GTP levels in unstimulated KG1 cells, no constitutive activation of Erk1,2 could be detected. Inactivation of Erk1,2 involves the dual specific protein phosphatase MKP-1 which dephosphorylates threonine 183 and tyrosine 185 of Erk1,2. Also PAC-1 that appears to be expressed solely in hematopoietic tissues in response to Erk activation, may be involved. 26, 27 Interestingly, studies in macrophages with high Raf expression showed constitutively expression of MKP-1 mRNA levels. 28 Therefore it is possible that in KG1 cells the sustained activation of Shc and Ras leads to constitutive MKP-1 or PAC-1 expression keeping Erk1,2 in quiescent cells in the inactive state. Experiments with the tyrosine phosphatase inhibitor orthovanadate confirm this hypothesis, as MKP-1 is sensitive to orthovanadate. 29 Treatment of quiescent KG1 cells with vanadate induces activation of Erk1,2 (Figure 2c ). This finding suggest that tyrosine phosphatases are likely to be involved in the activation of Erk1,2 in KG1 cells despite the presence of constitutive Shc and Ras activation.
In conclusion, we show that activation of Erk1,2 is essential for proliferation of growth factor-dependent and -independent leukemic cells. Even the short-lived and rapid activation of Erk1,2 that occurs in response to FBS in KG1 cells is essential for proliferation.
